These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37598014)

  • 1. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
    Guédon C; Tauber M; Linder C; Paul C; Shourick J
    Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
    [No Abstract]   [Full Text] [Related]  

  • 2. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study.
    Pezzolo E; Rossi M; Caroppo F; Bianchelli T; Belloni Fortina A; Giacchetti A; Calzavara Pinton P; Naldi L
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e757-e759. PubMed ID: 36662631
    [No Abstract]   [Full Text] [Related]  

  • 4. Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study.
    Kang DH; Kwon SH; Lew BL
    J Dermatol; 2024 Mar; 51(3):e63-e65. PubMed ID: 37950501
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.
    Keow S; Abu-Hilal M
    J Am Acad Dermatol; 2024 Oct; 91(4):734-735. PubMed ID: 38857764
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study.
    Jo CE; Georgakopoulos JR; Ladda M; Ighani A; Mufti A; Drucker AM; Piguet V; Yeung J
    J Am Acad Dermatol; 2020 Jun; 82(6):1530-1532. PubMed ID: 32074486
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab use in atopic dermatitis and beyond in skin diseases.
    Fourzali K; Golpanian RS; Yosipovitch G
    Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.
    Cioppa V; Lazzeri L; Carraro A; De Piano E; Falcinelli F; Galluzzo M; Pallotta S; De Pità O; Russo F
    Dermatitis; 2024; 35(S1):S107-S108. PubMed ID: 37594754
    [No Abstract]   [Full Text] [Related]  

  • 12. Dupilumab for moderate-severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States.
    Emmerich VK; Williams JA; Hrin ML; Feldman SR; Strowd LC
    Int J Dermatol; 2024 Apr; 63(4):524-525. PubMed ID: 38093434
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

  • 14. Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study [Formula: see text].
    Jo CE; Georgakopoulos JR; Ladda M; Ighani A; Mufti A; Drucker AM; Piguet V; Yeung J
    J Cutan Med Surg; 2020; 24(5):468-473. PubMed ID: 32442020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
    J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.
    Zhou B; Peng C; Cao Q; Wang J; Chen X; Li J
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e35-e38. PubMed ID: 37565387
    [No Abstract]   [Full Text] [Related]  

  • 17. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.
    Akuffo-Addo E; Nicholas MN; Lansang P
    J Cutan Med Surg; 2023; 27(2):177-178. PubMed ID: 36721993
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Dupilumab for Severe Atopic Dermatitis Co-occurring With Asthma in a Real-World Setting.
    Pose K; Laorden D; Hernández N; Villamañán E; Quirce S; Domínguez-Ortega J
    J Investig Allergol Clin Immunol; 2023 Jun; 33(3):217-219. PubMed ID: 37318773
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.